title: Small cell lung carcinoma: staging, imaging, and treatment considerations.
abstract: Small cell lung carcinoma (SCLC) is the most common primary pulmonary neuroendocrine malignancy and is characterized by a rapid doubling time and high growth fraction. Approximately 60%-70% of patients present with metastatic disease at the time of diagnosis, and their prognosis is poor. However, improved survival has been demonstrated when SCLC is diagnosed early and specific treatment strategies are used. A modified version of the Veterans Administration Lung Cancer Study Group (VALSG) staging system has traditionally been used to categorize SCLC as limited-stage or extensive-stage disease to guide therapy. However, the International Association for the Study of Lung Cancer has recommended that the current seventh edition of the American Joint Committee on Cancer tumor-node-metastasis staging system for lung cancer replace the VALSG system for staging of SCLC. Appropriate staging and patient management require knowledge of imaging manifestations of SCLC across multiple imaging modalities, the strengths and weaknesses of specific examinations, the correlation of these findings with the staging criteria used in clinical practice, and the impact of appropriate staging on patient treatment and survival. Computed tomography (CT) is primarily used to evaluate the primary tumor and the extent of intrathoracic disease. In recent years, however, 2-[fluorine-18]fluoro-2-deoxy-d-glucose positron emission tomography/CT has proved to be more accurate than conventional imaging in the staging of SCLC and can be used to guide therapy and assess treatment response.
authors.affiliation: From the Department of Diagnostic Radiology, Division of Diagnostic Imaging (B.W.C., M.T.T., J.J.E.), and Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine (B.S.G.), University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1478, Houston, TX 77030.
authors.forename: Brett W
authors.initials: BW
authors.lastname: Carter
authors.forename: Bonnie S
authors.initials: BS
authors.lastname: Glisson
authors.forename: Mylene T
authors.initials: MT
authors.lastname: Truong
authors.forename: Jeremy J
authors.initials: JJ
authors.lastname: Erasmus
mesh_terms: D003287:Contrast Media; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy; D064847:Multimodal Imaging; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D019275:Radiopharmaceuticals; D055752:Small Cell Lung Carcinoma / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy; D014057:Tomography, X-Ray Computed / Q000379:methods*; D014481:United States
chemical_list: D003287:Contrast Media; D019275:Radiopharmaceuticals